STOCK TITAN

Gilead (GILD) executive sells 3,000 shares in planned trade

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Gilead Sciences executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of Gilead common stock in an open‑market transaction at a price of $144.23 per share. After this sale, she directly holds 131,779 shares of Gilead common stock.

The filing notes that this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 20, 2025, indicating it was scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mercier Johanna

(Last) (First) (Middle)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CA 94404

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Comm & Corp Aff Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/16/2026 S(1) 3,000 D $144.23 131,779 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Remarks:
/s/ Amy Kim by Power of Attorney for Johanna Mercier 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gilead (GILD) executive Johanna Mercier report in this Form 4?

Johanna Mercier reported an open‑market sale of 3,000 shares of Gilead common stock at $144.23 per share. Following the transaction, she directly holds 131,779 shares, as disclosed in the Form 4.

At what price did Johanna Mercier sell Gilead (GILD) shares?

She sold 3,000 Gilead shares at a price of $144.23 per share. The transaction was classified as an open‑market or private sale, according to the Form 4 transaction code and description.

How many Gilead (GILD) shares does Johanna Mercier own after this sale?

After the reported sale, Johanna Mercier directly owns 131,779 shares of Gilead common stock. This figure reflects her holdings immediately following the 3,000‑share open‑market transaction disclosed in the Form 4.

Was Johanna Mercier’s Gilead (GILD) share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was made under a Rule 10b5‑1 trading plan adopted on February 20, 2025. Such plans pre‑schedule trades, reducing the significance of trade timing decisions.

What role does Johanna Mercier hold at Gilead (GILD)?

Johanna Mercier serves as Gilead’s Chief Commercial & Corporate Affairs Officer. The Form 4 identifies her as an officer of the company, and the reported Gilead share sale relates to her directly held common stock.
Gilead Sciences Inc

NASDAQ:GILD

View GILD Stock Overview

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

180.27B
1.24B
Drug Manufacturers - General
Biological Products, (no Diagnostic Substances)
Link
United States
FOSTER CITY